AIFF - Rasio kapitalisasi pasar marang pendapatan Firefly Neuroscience Inc
Cyber threats and digital sovereignty are forcing Firefly Neuroscience, Inc (AIFF) to invest in data security, which impacts the company's revenue valuation. The current level of 7.40 reflects the state of this parameter amid steady demand for neurodiagnostics regardless of economic conditions. The environmental footprint is minimized through cloud technologies, creating a stable asset profile on the chart.
Rincian metrik lan analitis perusahaan Firefly Neuroscience Inc (AIFF)
- kuotasi saiki lan rata-rata prakiraan nilai:
- statistik kapitalisasi pasar:
- indikator kapitalisasi buku:
- indikator beban kredit lan likuiditas emiten:
Total Utang marang Modal Firefly Neuroscience, Inc|AIFF - Utang jangka dawa marang ekuitas|Rasio tanggungan utang jangka cendhak marang modal Firefly Neuro|AIFF - Utang perusahaan|Utang-utang marang nilai buku Firefly Neuro|AIFF - Utang jangka dawa perusahaan|Gunggunge utang jangka cendhak Firefly Neuroscience|Indikator likuiditas cepet fireflyneuro.com
- indikator pendapatan resik lan kelipatan nilai:
AIFF - Bathi resik|Prakiraan bathi perusahaan Firefly Neuroscience, Inc|AIFF - Pangali P/E|Rasio prakiraan rega marang bathi Firefly Neuroscience, Inc.|AIFF - Rasio rega marang bathi tumrap wutah|Nilai perusahaan marang bathi operasional sadurunge panyusutan Firefly Neuro|AIFF - Bathi operasional EBITDA|Bathi resik saben saham sajrone 12 wulan pungkasan Firefly Neuroscience|AIFF - Bathi resik saben saham (EPS TTM)|Wutah bathi saben saham ing petungan tahunan sajrone rolas wulan pungkasan fireflyneuro.com|AIFF - Wutah bathi resik saben saham ing taun iki|Dinamika bathi saben saham sing diarepake ing taun ngarep Firefly Neuroscience, Inc
- rincian pendapatan lan dodolan emiten:
Analisis fundamental perusahaan:AIFF - fireflyneuro.com
Firefly Neuroscience, Inc (AIFF) is implementing AI-driven EEG analysis for high-precision diagnostics of mental disorders, creating significant added value. The P/S ratio measures market capitalization relative to sales volume, allowing for an assessment of the value of each unit of revenue. By analyzing the historical P/S chart, an investor can uncover hidden revenue manipulations by searching for anomalous gaps in the trend. Current values reflect market expectations regarding the scaling pace of this innovative brand.
Pesaing Firefly Neuroscience, Inc
BIIB - Rega marang dodolan|Neurocrine Biosciences, Inc. - Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan RGC|AXSM - Rasio rega marang pendapatan|ACAD (ACADIA Corp) - Rasio kapitalisasi marang pendapatan|XENE: Multiplikator P/S|Rega marang dodolan vikingtherapeutics.com (VKTX)|Kapitalisasi marang pendapatan SUPN|Multiplikator P/S Catalyst Pharma|Rasio rega marang pendapatan Denali Therapeutics Inc (DNLI)|HRMY (Harmony Corp) - Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Biohaven Ltd. BHVN|amylyx.com (AMLX) - Rega marang dodolan|TRVI - Rasio rega marang pendapatan|Koefisien rega marang pendapatan Praxis Precision Medicines Inc PRAX|AVXL: Multiplikator P/S|Kapitalisasi marang pendapatan CeriBell EEG|PRTA (Prothena Biosciences) - Multiplikator P/S|Alector Therapeutics (ALEC) - Koefisien rega marang pendapatan|Multiplikator P/S ANNX|OMER - Rega marang dodolan|Rasio rega marang pendapatan Neurogene Corp NGNE|ACIU: Rasio kapitalisasi marang pendapatan|Voyager Therapeutics - Multiplikator P/S|neumoratx.com (NMRA) - Kapitalisasi marang pendapatan|SCLX: Multiplikator P/S|Rega marang dodolan Tevogen Bio Holdings Inc. (TVGN)|Kapitalisasi marang pendapatan ACOG|CGTX: Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S IKT|Koefisien rega marang pendapatan cassavasciences.com|Rasio rega marang pendapatan Assertio ASRT|COYA: Rasio kapitalisasi marang pendapatan|VistaGen Therapeutics Inc - Multiplikator P/S|Ovid Therapeutics Inc. (OVID) - Kapitalisasi marang pendapatan|ABOS: Multiplikator P/S|cervomed.com (CRVO) - Multiplikator P/S|ATHE (Alterity Therapeutics Ltd.) - Multiplikator P/S|Clene Nanomedicine (CLNN) - Koefisien rega marang pendapatan|Multiplikator P/S PEPG|JUNS: Rasio rega marang dodolan|Multiplikator P/S RLMD (Relmada Therapeutics)|ANVS (annovisbio.com) - Rasio rega marang dodolan|GRCE - Rasio rega marang pendapatan|KLTO (Klotho Neurosciences Inc) - Rasio kapitalisasi marang pendapatan|NRSN: Multiplikator P/S|Rega marang dodolan Reviva Pharmaceuticals, Inc. (RVPH)|Kapitalisasi marang pendapatan MTVA|Multiplikator P/S neuraxis.com|Rasio rega marang pendapatan Helius Medical (HSDT)|PASG (passagebio.com) - Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Neuphoria Therapeutics NEUP|Minerva (NERV) - Rega marang dodolan|Athira Pharma, Inc. - Multiplikator P/S|Rasio rega marang dodolan ADXN|ALZN: Multiplikator P/S|CYCN - Koefisien rega marang pendapatan|Rasio rega marang pendapatan Protagenic Therapeutics Inc.|KTTA: Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S CRGT|ATXI - Rega marang dodolan|Multiplikator P/S BCLI (BrainStorm Cell Therapeutics)|CARA (Cara Therapeutics Inc.) - Rasio rega marang dodolan|CHRO - Rasio rega marang pendapatan|ELYM: Rasio rega marang pendapatan|ITCI (intracellulartherapies.com) - Kapitalisasi marang pendapatan|Rega marang dodolan longboardpharma.com (LBPH)|Kapitalisasi marang pendapatan MRNS|NKGN: Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan NeuroBo (NRBO)|Sage Therapeutics Inc - Rasio kapitalisasi marang pendapatan|Multiplikator P/S SNPX (Synaptogenix, Inc.)|trevena.com (TRVN) - Rega marang dodolan|VIGL: Kapitalisasi marang pendapatan|WENA - Multiplikator P/S|Cerevel (CERE) - Rasio rega marang pendapatan
